Four of the incubator’s portfolio companies will pitch to investors at the GCV Digital Forum 3.0 following the success of similar competitions at our previous events.
Tony Raven, CEO of Cambridge Enterprise and a GUV Lifetime Achievement awardee, will step down by the end of next year.
The world’s number one incubator has been making a big impact since 2002, having supported more than 4,000 entrepreneurs that have raised more than $2.2bn between them.
Cellular Agriculture was spun out of University of Bath in 2016 as the UK’s first startup in the cultured meat space, but its ambitions go far beyond a lab-grown burger.
Goldwind, Legal & General and Equinor have all taken part in a series D that achieved a $41m first close and boosted the Oxford spinout’s total equity and debt to more than $118m.
ICL vascular implant spinout Veryan Medical has been bought by medical device firm Otsuka after raising $56m from investors including IP Group.
Orchard Therapeutics has listed in the US following a $200m initial public offering that came just three years after the gene therapy developer was spun out of UCL.
Ziylo, a spinout from University of Bristol that is working on a diabetes treatment, has been acquired by Novo Nordisk for a total that could exceed $800m.